|
Condom technology leaps forward with radical design concepts for the 21st century and the most significant structural changes since latex condoms were introduced in 1920. Three unique condom prototypes that begin US clinical research this summer could reshape the future landscape of the latex-dominated condom industry. Could the new ORIGAMI CondomsT mark the end of an era for the old latex condom?
Los Angeles, CA (PRWEB) June 23, 2011 - Condom technology has taken a major leap forward with
radical design concepts for the 21st century and the most significant structural changes since latex condoms were first introduced in
1920. Three patent-pending prototypes that begin US clinical research this summer could reshape the future landscape of the
latex-dominated condom industry worldwide. According to Danny Resnic, the Los Angeles based inventor,
"The new ORIGAMI Condoms T could mark
the end of an era for the old latex condom. The brand has re-invented condoms as we have known
them. The prototypes are non-rolled, non-latex, non-allergenic, and they were independently
tested by the leading microbiology lab." The global condoms market is forecast to reach
27 billion units and US $6 billion annually by the year 2015. Capturing a 5% market
share would exceed US $300 million in gross annual sales for Resnic's company.
Resnic's Los Angeles design firm, Strata Various Product Design, was fully funded with $2.2 million in SBIR awards from
the National Institute of Allergies & Infectious Diseases (NIAID) and The Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD), to research and develop its novel inventions, the first condom production made of biocompatible, non-allergenic silicone.
Resnic is the principal investigator for three Phase I Feasibility & Acceptability Studies designed as
clinical research in the fields of HIV prevention and contraception. Resnic, who studied at the Art Center College of Design,
developed the array of condoms designed to increase pleasure and to simultaneously improve safety. The adjective
'sensational' rarely appears in the same sentence with condoms, however, the brand's technological innovations
are intended to advance consumer acceptability by introducing condoms that actually feel sensational to use,
potentially increasing condom use compliance on a global scale. Leading US consultants to the projects are
Ray Chavez, Projects Coordinator; Dr. Vanessa Moll, MD; Dr. Kathleen Morrow, PhD; Tricia Evenson, Carla
Calmenson, Ariana Salas, Jim Eldon, Eric Lai, and Dennis Bui.
The ORIGAMI Male CondomT (OMC) would be the first non-rolled condom to enter the market. This significant
advancement could eliminate difficulties typically associated with unrolling a condom, a critical issue among condom users that can
disrupt intimacy and contribute to the loss of an erection. The OMC is designed to don in a fraction of the time required for
rolled latex condoms. Resnic's custom formulated silicone developed for this application provides super elongation that
facilitates a true 'one-size-fits-all'. Clinical research will be conducted in collaboration with two eminent US
researchers, Ron Frezieres and Terri Walsh, at the CA Family Health Council in Los Angeles.
Resnic's ORIGAMI Female CondomT (OFC) is a unique device that would be under a woman's full control with an active voice
in the decision to use a condom. The OFC is designed to insert comfortably as a small device that subsequently extends to its full
length during intercourse. It is intended to be more manageable and more pleasurable than commercial products currently available
in the female condom category. Clinical research is planned in collaboration with co-Investigator, Dr. Ariane van der Straten,
PhD, director of the Women's Global Health Imperative at RTI International, San Francisco.
A third, and revolutionary concept, the ORIGAMI R.A.I. CondomT developed by the inventor, is the first of its type
exclusively for receptive anal intercourse, which is widely practiced among heterosexual couples as well as gay men. This device,
made of medical grade silicone, is designed to insert easily. The active male partner would not need to wear a condom. The
device is compatible with the relevant human anatomy and it has an inconspicuous, transparent outer rim that retains the
device in position. The study collaborates with co-Investigator, Dr. Kenneth Mayer, MD, Medical Research Director and
Co-Chair of The Fenway Institute, in Boston.
Each of these initial Phase I human studies will be followed with larger, Phase II research. The data will then be submitted
for pre-market review by various regulatory agencies such as the World Health Organization (WHO) in Geneva, the CE-Mark in Europe, and the
FDA in the United States. A product launch is anticipated by April, 2014.
Consumers who wish to be among the first 5000 to order the ORIGAMIT brand innovations, are invited to reserve their product
choices on a company website: http://www.origamicondoms.com/ . Pending
regulatory approvals, the contact list will be notified of availability, in sequence by the reservation date.
The company intends to license the ORIGAMI CondomT brand for global marketing and distribution. Licensing is managed for the
design firm by the Biomedical & Biotech Division at Foresight Science & Technology, Inc.T
###
For further information, photos, or to request an interview with Mr. Resnic, please contact:
Ray Chavez, Media Contact
Strata Various Product Design
Los Angeles, CA USA
310-280-9861
rayc1588@gmail.com
The OMC project described was supported by Award #1 R43 HD050805-01A1, from the Eunice Kennedy Shriver National Institute
of Child Health & Human Development (NICHD). The content is solely the responsibility of the authors and does not necessarily
represent the official views of the NICHD or the National Institutes of Health.
The OFC project (Award #1R43AI091574-01A2) an the R.A.I. project (Award #1R43AI084145-01A1) described, were supported by
Awards from the National Institute of Allergy and Infectious Diseases (NIAID). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the NIAID or the National Institutes of Health.
|
